Recent Updates
Recently added Catalysts
ALLO

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

Key Takeaway: Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Price reaction · baseline $8.82 (2022-03-09 close) · hit after-hours · clean, no other ALLO news in the window
day 0 close
-1.2%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
5.6%
average across 5 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
ALLO-715
Phase 1 · Relapsed/Refractory Multiple Myeloma

Full Press Release Details

Newport Beach, CALIFORNIA, March 10, 2022 (GLOBE NEWSWIRE) -- Agtech Global International, Inc. (Agtech) (OTC Pink: AGGL) announces that due to unexpected delays in Agtech’s funding of the purchase, the final consummation of the Memorandum of Understanding between Dr. Malcolm A. Leissring and the planned acquisition of his company NooMeds, LLC. will not proceed and is hereby terminated.
As a result of this change, Dr. Leissring will not continue in the consulting role as Chief Scientific Officer and Agtech will not have any future involvement with the AD Foundation.
Agtech is publicly traded on the OTC Markets (OTC Pink: AGGL). Headquartered in Newport Beach, California, Agtech is entering the rapidly developing markets for premium CBD consumer products through its recent acquisition of Galexxy Corporation and its joint venture with City Farm Industries. Agtech’s “soil-to-sale” business strategy is keenly focused on controlling the supply chain and maximizing profits.
Agtech Global International, Inc.Ross Lyndon-JamesE:ross@galexxy.comM: (949) 456 3972

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this press release.
Last updated: Mar 10, 2022